Trials / Active Not Recruiting
Active Not RecruitingNCT05228158
A Study of Tazemetostat on Safety in Participants With Relapsed or Refractory Follicular Lymphoma With Enhancer of Zeste Homolog 2 (EZH2) Gene Mutation in Japan
A Post-marketing Observational Study of Tazemetostat on Safety in Patients With Relapsed or Refractory Follicular Lymphoma With EZH2 Gene Mutation in Japan
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 145 (estimated)
- Sponsor
- Eisai Co., Ltd. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The primary purpose of the study is to investigate the safety of tazemetostat in participants with relapsed or refractory follicular lymphoma with EZH2 gene mutation under daily clinical practice.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tazemetostat | Tazemetostat oral tablets. |
Timeline
- Start date
- 2021-08-16
- Primary completion
- 2028-03-31
- Completion
- 2028-03-31
- First posted
- 2022-02-08
- Last updated
- 2026-01-02
Locations
135 sites across 1 country: Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05228158. Inclusion in this directory is not an endorsement.